Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Norwood, MA, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a rare and life-threatening multi-system autoimmune disease for which there are currently no U.S. Food and Drug Administration (FDA)-approved treatments for overall disease.

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call Transcript

Norwood, MA, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates.

Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates

Norwood, MA, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in  D ETER M INE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). The Company expects to report topline results from this study in the fourth quarter of 2021.

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Norwood, MA, July  30, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its second quarter financial results on Thursday, August 6. Corbus management will host a conference call and live audio webcast to discuss operational and financial results at 8:30 a.m. ET that same day.

Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020 

Norwood, MA, July  29, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it has received an aggregate of $71 million in gross proceeds from its at-the-market (“ATM") offering coupled with the execution of a $50 million debt financing facility with K2 HealthVentures (“K2HV”), a healthcare-focused specialty finance company.

Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital

After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 Data

GW Pharmaceuticals

What’s the choice between these U.K and U.S. biotech-cannabis companies?

Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals

Norwood, MA, July  08, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the appointment of George Golumbeski, Ph.D., to its Board of Directors.

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

Norwood, MA, June  29, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of 3 abstracts at the 6th Systemic Sclerosis World E-Congress. The data presented in these abstracts show that the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (ACR CRISS) score positively correlates with improvements in multiple patient-reported outcomes. Importantly, the ACR CRISS score also correlates more strongly with these patient-reported outcomes than change in modified Rodnan Skin Score (mRSS). Together, these data show that the ACR CRISS score broadly reflects changes from baseline in how patients feel and function.   These data will be presented in a recorded oral presentation and two e-posters at the 6th Systemic Sclerosis World E-Congress on June 29, 2020. Two live discussions sessions for the oral presentation will be held during the Live Congress on July 12, 2020 at 16:00-16:30 UCT+2 (Rome, Italy) time and on July 13, 2020 at 11:30-12:00 UCT+2 (Rome, Italy) time. All three abstracts will be published in the Journal of Scleroderma and Related Disorders.  In addition, the Company announced it will sponsor a satellite symposium titled “The Role of the Endocannabinoid System in Chronic Inflammation and Fibrosis” hosted by Professor Christopher Denton, MB, BS, PhD, FRCP, Head of Centre and Consultant Rheumatologist, University College London Division of Medicine, and Tracy Frech, M.D., MS, Director of the Systemic Sclerosis Clinic at the University of Utah Hospital and the Director of Clinical Trials for the Division of Rheumatology. The symposium will be held at the Live Congress on Sunday, July 12, 2020 at 14:30 UCT+2 (Rome, Italy) time. Once the presentation is made public, it will be available along with the three abstracts on the Company’s website in the  Scientific Conferences  section.

Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress

Norwood, MA, June  22, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed their final visit in the Company’s Phase 2b JBT101-CF-002 trial of lenabasum for the treatment of cystic fibrosis. Topline results from the study are on track to readout in the third quarter of 2020, following the topline data from the RESOLVE-1 Phase 3 systemic sclerosis study.

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?

Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?

Norwood, MA, June  01, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced baseline patient demographics and disease characteristics in its Phase 2b study of lenabasum in cystic fibrosis. The information was published in an electronic supplement of the Journal of Cystic Fibrosis in connection with the 43rd European Cystic Fibrosis Conference. Topline results from the Phase 2b cystic fibrosis study are on track for the summer of 2020.  Summarized below is the abstract title that was selected for publication. The abstract is available in the  Scientific  Publications  section of Corbus’  website .    Abstract Number  ePS3.10:

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

Norwood, MA, May  27, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed their final visit in the Company’s RESOLVE-1 Phase 3 trial of lenabasum for the treatment of systemic sclerosis. Topline results from the study are on track for summer 2020.

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Norwood, MA, May  22, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2020 E-Congress that will be taking place June 3-6, 2020.

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q1 2020 Results - Earnings Call Transcript

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 0.00% and 7.44%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell 1.3% in pre-market trading after the company reported Q1 results.

Corbus Pharmaceuticals: Q1 Earnings Insights

Norwood, MA, May  11, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the first quarter of 2020. The Company also provided clinical and corporate updates.

Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

Norwood, MA, April  29, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the publication of results from the double-blind, randomized, placebo-controlled Phase 2 trial assessing the safety and efficacy of lenabasum in 42 patients with diffuse cutaneous systemic sclerosis in Arthritis & Rheumatology. The  paper  [doi:10.1002/art.41294] is titled “Safety and efficacy of lenabasum in a Phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis.” As previously reported, data showed treatment with lenabasum was associated with improvements across the primary endpoint, the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (ACR CRISS) score and multiple secondary efficacy outcomes. The study results also demonstrated that lenabasum has an acceptable safety profile.

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

Arena Pharmaceuticals

Trulieve Cannabis Corp.

Not all pot stocks are wildly volatile, and there are safer options out there for cannabis investors.

3 Reasons Medical Marijuana Is a Better Long-Term Investment Than Recreational Pot

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Implied Volatility Surging for Corbus (CRBP) Stock Options

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q4 2019 Results - Earnings Call Transcript

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -20.59% and -44.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Corbus Pharmaceuticals Holdings Stock (CRBP)